证券代码： 600682 证券简称：南京新百 公告编号：临2023-037 南京新街口百货商店股份有限公司 第十届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司(以下简称公司)第十届董事会第七次会 议(以下简称会议)于2023年12月15日以通讯表决的方式召开。会议通知于2023年 12月12日以电话或邮件的方式向全体董事发出，本次会议应参会董事10人，实际参 会董事10人。本次会议的通知、召开以及参与表决董事人数均符合有关法律、法规 、规则及《公司章程》的规定。会议审议并通过了如下议案： 公司董事会非独立董事张雷先生因公司工作调整原因，向公司辞去公司董事 职务。根据《公司法》、《上海证券交易所股票上市规则》及《公司章程》的相关 规定和董事会提名委员会的提名及资格审查，经公司第十届董事会第七次会议审议 ，同意提名袁千惠女士为公司第十届董事会非独立董事候选人。其任期自股东大会 通过之日起至本届董事会任期届满为止。简历详见附件。 本议案尚需提交至公司股东大会审议。 表决结果 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-036 南京新街口百货商店股份有限公司 关于股东部分股份解除质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司股东银丰生物工程集团有限公司（以下简称银丰生物）持有南京新 街口百货商店股份有限公司（以下简称公司）股份数量为 96,722,192 股，占公 司总股本的 7.19%。本次股份解除质押及质押后，银丰生物累计质押数量为 61,184,164 股（含本次），占其持有公司股份数的 63.26%，占公司总股本的 4.55%， 剩余未质押股份数量为 35,538,028 股。 证券代码：600682 证券简称：南京新百 公告编号：临 2023-036 公司近日收到股东银丰生物关于其所持公司股份解除质押及质押登记的说 明，现将有关情况公告如下： | 股东名称 | 银丰生物工程集团有限公司 | | | | | | --- | --- | --- | --- | --- | --- | | 本次解质股份 | | | 32,357,2 ...

Revenue and Costs - Total operating revenue for the first three quarters of 2023 reached 4,756,623,138.17 yuan, compared to 4,663,340,447.80 yuan in the same period of 2022[13] - Total operating costs for the first three quarters of 2023 were 4,117,070,060.96 yuan, up from 3,802,240,866.18 yuan in the same period of 2022[13] - Revenue for the reporting period was 1,518,623,752.32 yuan, a decrease of 7.87% year-over-year[31] Assets and Liabilities - The company's total assets as of September 30, 2023, amounted to 25,840,412,408.24 yuan, compared to 25,215,359,602.91 yuan at the end of 2022[13] - Total liabilities as of September 30, 2023, were 7,002,517,134.24 yuan, slightly down from 7,042,748,127.18 yuan at the end of 2022[13] - Shareholders' equity increased to 18,837,895,274.00 yuan as of September 30, 2023, from 18,172,611,475.73 yuan at the end of 2022[13] - Total assets at the end of the reporting period were 25,840,412,408.24 yuan, an increase of 2.48% compared to the end of the previous year[31] - Total assets increased to 25,840,412,408.24 from 25,215,359,602.91[46] Cash Flow - Cash received from sales of goods and services was 6,164,623,872.53 RMB, slightly down from 6,202,219,632.53 RMB in the same period last year[23] - Cash paid for goods and services was 2,675,031,475.65 RMB, up from 2,544,170,156.61 RMB in the same period last year[23] - Cash paid to and for employees was 2,045,450,039.75 RMB, up from 1,884,610,341.70 RMB in the same period last year[23] - Total operating cash inflow was 6,603,735,229.30 RMB, slightly down from 6,644,652,967.26 RMB in the same period last year[23] - Total operating cash outflow was 6,045,258,617.07 RMB, up from 5,690,958,819.24 RMB in the same period last year[23] - Net cash flow from operating activities was 558,476,612.23 yuan, a decrease of 41.44% year-over-year[31] - Net cash flow from investing activities was -948,160,870.39 yuan, compared to -2,829,955,455.50 yuan in the same period last year[33] - Net cash flow from financing activities was 55,455,882.87 yuan, compared to -292,207,886.55 yuan in the same period last year[33] - Cash and cash equivalents at the end of the period were 4,591,462,944.89 yuan, a decrease from 4,872,456,964.62 yuan at the beginning of the period[33] Profit and Loss - Net profit attributable to parent company shareholders was 397,843,076.60 RMB, compared to 613,997,506.71 RMB in the same period last year[20] - Total comprehensive income for the period was 690,450,986.38 RMB, compared to 1,508,277,551.61 RMB in the same period last year[20] - Basic earnings per share were 0.30 RMB, compared to 0.46 RMB in the same period last year[23] - Net profit attributable to shareholders of the listed company was 76,110,777.25 yuan, a decrease of 65.06% year-over-year[31] - Net profit attributable to shareholders decreased by 65.06% in the current reporting period due to a decline in main business performance[39] - Net profit attributable to shareholders decreased by 35.20% from the beginning of the year to the reporting period due to a decline in main business performance[39] Expenses - R&D expenses were 200,084,818.54 RMB, up from 190,707,290.78 RMB in the same period last year[17] - Sales expenses were 416,552,910.93 RMB, down from 433,779,506.79 RMB in the same period last year[17] - Financial expenses decreased by 616.52% from the beginning of the year to the reporting period due to increased interest income[39] Inventory and Development - Inventory increased significantly to 470,660,482.11 yuan as of September 30, 2023, from 287,490,302.87 yuan at the end of 2022[11] - Development expenditure increased by 104.42% at the end of the reporting period due to the advancement of R&D projects[39] - Inventory increased by 63.71% at the end of the reporting period due to an increase in raw materials[39] Other Financial Metrics - The company's monetary funds decreased to 4,630,121,536.44 yuan as of September 30, 2023, from 4,934,614,531.76 yuan at the end of 2022[11] - Trade receivables slightly decreased to 1,195,214,918.13 yuan as of September 30, 2023, from 1,196,131,960.44 yuan at the end of 2022[11] - Fixed assets increased to 3,485,393,712.06 yuan as of September 30, 2023, from 2,999,939,557.56 yuan at the end of 2022[11] - Non-recurring gains and losses amounted to 7,463,478.51 yuan for the reporting period[38] - Government subsidies included in current profits were 1,134,781.13 yuan[38] - Fair value changes from financial assets and liabilities amounted to 9,852,734.34 yuan[38] - Other comprehensive income decreased by 61.09% at the end of the reporting period due to exchange rate fluctuations[39] - Credit impairment losses increased by 36.96% from the beginning of the year to the reporting period due to increased provisions[39] - Contract liabilities increased to 3,234,679,542.05 from 3,057,122,549.54[46] Shareholders - The company's total number of ordinary shareholders at the end of the reporting period was 38,388[5]

证券代码：600682 证券简称：南京新百 公告编号：临 2023-035 本司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）根据上海证券交易所《上市 公司自律监管指引第 3 号——行业信息披露》之《第四号——零售》的相关要求，现 将公司 2023 年第三季度主要经营数据（未经审计）公告如下： 一、2023 年前三季度主要经营数据如下： （一）主营业务分行业情况 | | | | 主营分行业 | 主营业务收入 | 主营业务成本 | 毛利率 | 营业收入比上年 | 营业成本比上年 | | --- | --- | --- | --- | --- | --- | | | | | （%） | 增减（%） | 增减（%） | | 商业 | 341,361,186.25 | 108,949,831.44 | 68.08 | -2.30 | -11.31 | | 房地产业 | 2,110,243.68 | 1,257,877.57 | 40.39 | 915.47 | 547.39 | | 宾馆餐饮业 ...

1、股份质押情况 重要内容提示： 公司股东银丰生物工程集团有限公司（以下简称银丰生物）持有南京新 街口百货商店股份有限公司（以下简称公司）股份数量为 96,722,192 股，占公 司总股本的 7.19%。本次股份质押后，银丰生物累计质押数量为 61,184,164 股 （含本次），占其持有公司股份数的 63.26%，占公司总股本的 4.55%，剩余未质 押股份数量为 35,538,028 股。 公司于 2023 年 10 月 17 日收到股东银丰生物关于其所持公司股份质押登记 的说明，现将有关情况公告如下： 一、本次股份质押基本情况 | 股东 | 是否为 | 本次质押 | 是否 | 是否 | 质押 | 质押 | | 占其所 | 占公司 | 质押融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 控股 | 股数（股） | 为限 | 补充 | 起始日 | 到期日 | 质权人 | 持股份 | 总股本 | 资金用途 | | | 股东 | | 售股 | 质押 | | | | 比例 | 比例 | | | 银丰 生 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-033 南京新街口百货商店股份有限公司 关于上海证券交易所有关募投项目预付款事项 监管工作函的回复公告 南京新街口百货商店股份有限公司（以下简称公司）于 2023 年 9 月 1 日收 到上海证券交易所下发的《关于南京新街口百货商店股份有限公司有关募投项 目预付款事项的监管工作函》（上证公函【2023】1065 号，以下简称工作 函）。公司对《工作函》所提到的事项进行了自查，现将自查结果回复如下： 前期，你公司对我部关于募集资金永久补流事项回函称，拟继续履 行与无锡市托米电子产品有限公司（以下简称托米电子）培训服务相关 合同，并确认与托米电子的采购非关联交易，不存在募集资金被直接或 间接占用、挪用等情形。近日有媒体报道称，托米电子控股股东窦怀峰 持有南京乐轩贸易有限公司（以下简称乐轩贸易）60%股份。乐轩贸易企 业联系号码与公司关联方江苏宏图高科技股份有限公司（以下简称宏图 高科）子公司江苏宏图高科软件工程有限公司曾存在重合，且乐轩贸易 曾被公司控股股东三胞集团在公开披露文件中列为关联方。此外，窦怀 峰为南京宁攀贸易有限公司（以下简称宁攀贸易 ...

华泰联合证券有限责任公司 关于上海证券交易所《关于南京新街口百货商店股份有限 公司有关募投项目预付款事项的监管工作函》回复 的核查意见 上海证券交易所： 独立财务顾问在 2022 年 4 月、2023 年 4 月，向上市公司发送备忘录和提示 函，书面提示公司合法合规使用募集资金，督促公司尽快实施项目或收回已支付 未使用的预付款。 根据贵所出具的《关于南京新街口百货商店股份有限公司有关募投项目预付 款事项的监管工作函》（上证公函【2023】1065 号）的有关要求，华泰联合证券 有限责任公司（以下简称"独立财务顾问"）作为南京新街口百货商店股份有限 公司（以下简称"南京新百"、"上市公司"或"公司"）发行股份购买安康通 控股有限公司 84%股权、Sanpower International Healthcare Group Co.,Ltd.100%股 权以及山东省齐鲁干细胞工程有限公司 76%股权并募集配套资金暨关联交易的 独立财务顾问及持续督导机构，对监管工作函所列问题认真进行了逐项落实，现 对涉及独立财务顾问发表意见的问题进行回复，请予审核。 问题：独立财务顾问持续督导期间是否已关注托米电子与公司控股股东及 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2023-032 南京新街口百货商店股份有限公司 关于股东部分股份解除质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次银丰生物还对其持有的公司股份进行了质押，详情如下： | 股东 | 是否 | 本次质押股数 | 是否 | 是否补 | 质押起始 | 质押到期 | 质权人 | 占其所 | 占公司 | 质押融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 为控 | （股） | 为限 | 充质押 | 日 | 日 | | 持股份 | 总股本 | 资金用途 | | | 股股 | | 售股 | | | | | 比例 | 比例 | | | | 东 | | | | | | | | | | 1、股份质押情况 重要内容提示： 公司股东银丰生物工程集团有限公司（以下简称银丰生物）持有南京新 街口百货商店股份有限公司（以下简称公司）股份数量为 96,722,192 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 3.24 billion, representing a 7.40% increase compared to RMB 3.01 billion in the same period last year[12]. - The net profit attributable to shareholders of the listed company decreased by 18.79% to approximately RMB 321.73 million, down from RMB 396.15 million in the previous year[12]. - The net cash flow from operating activities was approximately RMB 414.22 million, a decline of 39.07% compared to RMB 679.78 million in the same period last year[12]. - Basic earnings per share for the first half of 2023 were CNY 0.24, a decrease of 17.24% compared to the same period last year[37]. - The weighted average return on equity for the first half of 2023 was 1.86%, down from 2.26% in the previous year[37]. - The company achieved operating revenue of 3.238 billion yuan, with a net profit attributable to shareholders decreasing by 74 million yuan, a decline of 18.79% year-on-year[84]. Assets and Liabilities - The net assets attributable to shareholders of the listed company increased by 3.42% to approximately RMB 17.54 billion, compared to RMB 16.96 billion at the end of the previous year[12]. - Total assets rose by 2.79% to approximately RMB 25.92 billion, up from RMB 25.22 billion at the end of the previous year[12]. - The total assets at the end of the reporting period amounted to ¥25,919,000,000, with cash and cash equivalents accounting for 19.91% of total assets[119]. - The company’s inventory increased by 67.02% to ¥480,164,250.64, primarily due to an increase in raw materials[119]. - The company’s contract liabilities rose by 4.23% to ¥3,186,585,920.84, indicating growth in prepayments received[119]. - The company reported a loan balance of 310 million yuan as of June 30, 2023, secured by the outpatient building and corresponding land use rights of its subsidiary, Xuzhou New Health Geriatric Hospital Co., Ltd.[182]. Business Operations - The company operates primarily in the department store retail sector, with a business model that includes joint ventures and leasing[28]. - The company continues to enhance the synergy between its nursing business and private pay services, with a total of 4.5 million hours of nursing services provided during the reporting period[14]. - Ankangtong's revenue in the first half of 2023 showed a year-on-year growth, with home care services remaining the primary business segment, while long-term care insurance's share increased[34]. - The company has successfully won over 200 projects, including home care services in Xiangcheng and Tonglu, and has expanded into new provinces such as Liaoning and Anhui in the first half of 2023[34]. - The company has established over 100 smart elderly care command centers across various regions, enhancing its operational capabilities[34]. - The company is focusing on expanding its business areas while maintaining existing operations in home and community elderly care[56]. Market and Competition - The company faces operational risks due to macroeconomic downturns and market competition, which investors should be aware of[15]. - The company faces market competition risks in the healthcare sector, with increasing competition from state-owned enterprises and industry leaders entering the market[169]. - The company is facing intensified competition in the mCRPC treatment market, with multiple competing products available[175]. - The company is monitoring the impact of declining birth rates on its core business, which relies on newborn delivery volumes[170]. Strategic Initiatives - The company aims to integrate technology with traditional elderly care services, enhancing its service delivery through innovative solutions[30]. - The company has established strong strategic partnerships with major hospitals, enhancing its service network and resource availability[46]. - The company has established strategic partnerships with China Telecom, China Bank, and New Hope Gas to expand its service and sales channels[115]. - The company is actively pursuing the acquisition of projects in the UK to enhance international influence[57]. - The company is committed to increasing research and development efforts in stem cell technology to maintain its competitive edge in the industry[46]. Social Responsibility and Community Engagement - The company has implemented a series of community activities to support elderly care, such as cognitive impairment awareness events and volunteer assistance programs[34]. - The company is actively involved in formulating national standards, contributing to the development of the elderly care industry[56]. - The company has been actively involved in social responsibility initiatives, including the "Fire Seed Project," which has assisted nearly 200 children with blood diseases since 2013[91]. - The company is committed to social responsibility by engaging in public welfare activities to assist children with blood diseases[145]. Research and Development - The company is focusing on optimizing its brand structure and positioning to improve customer experience and brand recognition[95]. - The company is actively promoting early indications research for prostate cancer treatment, with the PROVENGE study entering its final phase[124]. - The company has evaluated over 200 projects since 2022 to develop a pipeline of immune therapy products, leveraging the stable cash flow from PROVENGE[92]. - The company is expanding its market presence by establishing a one-stop industrialization solution for domestic cell immunotherapy companies[77]. - The company is committed to enhancing service standards and patient experience through continuous training and resource optimization[83].

江苏泰和律师事务所 法律意见书 关于南京新街口百货商店股份有限公司 2023 年第二次临时股东大会的 法律意见书 泰和律师事务所 法律意见书 江苏泰和律师事务所 关于南京新街口百货商店股份有限公司 2023 年第二次临时股东大会的 法律意见书 致：南京新街口百货商店股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》、中国证券监督 管理委员会《上市公司股东大会规则》（以下简称"《股东大会规则》"）、《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》（以下简称"《自律 监管指引第 1 号》"）等法律、法规、规范性文件和《南京新街口百货商店股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，江苏泰和律师事务 所（以下简称"本所"）接受南京新街口百货商店股份有限公司（以下简称"公 司"）的委托，指派律师（以下简称"本所律师"）出席公司 2023 年第二次临 时股东大会（以下简称"本次股东大会"、"会议"），并出具本法律意见书。 为出具本法律意见书，本所律师依据《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则(试行)》等规定，严格履行了法定职 责，遵循了勤勉 ...